Recognition and management of dyslipidemia in children and adolescents

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 11, 2008, Pages 4200-4209

  Kwiterovich Jr , Peter O ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COLESEVELAM; COLESTYRAMINE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; STATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; DIET THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENDEMIC DISEASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID ANALYSIS; METABOLIC SYNDROME X; NEPHROTIC SYNDROME; OBESITY; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 57349161570     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1270     Document Type: Review

References (119)

1. McGill Jr HC, McMahan CA, Zieske AW, Sloop GD, Walcott JV, Troxclair DA, Malcom GT, Tracy RE, Oalmann MC, Strong JP 2000 Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 20:1998-2004
2. Berenson GS, Srinivasan SR, Bao W, Newman 3rd WP, Tracy RE, Wattigney WA 1998 Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 338:1650-1656
3. Mahoney LT, Burns TL, Stanford W, Thompson BH, Witt JD, Rost CA, Lauer RM 1996 Coronary risk factors measured in childhood and young adult life are associated with coronary calcification in young adults: the Muscatine Study. J Am Coll Cardiol 27:277-284
4. Davis PH, Dawson JD, Riley WA, Lauer RM 2001 Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation 104:2815-2819
5. Li S, Chen W, Srinivasan SR, Bond MG, Tang R, Urbina EM, Berenson GS 2003 Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA 290:2271-2276
6. Gidding SS, McMahan CA, McGill HC, Colangelo LA, Schreiner PJ, Williams OD, Liu K 2006 Prediction of coronary artery calcium in young adults using the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) risk score: the CARDIA study. Arch Intern Med 166:2341-2347
7. McMahan CA, Gidding SS, Viikari JS, Juonala M, Kähönen M, Hutri-Kähönen N, Jokinen E, Taittonen L, Pietikäinen M, McGill HC Jr., Raitakari OT 2007 Association of Pathobiologic Determinants of Atherosclerosis in Youth risk score and 15-year change in risk score with carotid artery intima-media thickness in young adults (from the Cardiovascular Risk in Young Finns Study). Am J Cardiol 100:1124-1129
8. Juonala M, Viikari JS, Ronnemaa T, Marniemi J, Jula A, Loo B-M, Raitakari OT 2008 Associations of dyslipidemias from childhood to adulthood with carotid intima-media thickness, elasticity, and brachial flow-mediated dilatation in adulthood. The Cardiovascular Risk in Young Finns Study. Arterioscler Thromb Vasc Biol 28:1012-1017
9. Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang KY, Levine DM 1993 Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 328:313-318
10. Lee J, Lauer RM, Clarke WR 1986 Lipoproteins in the progeny of young men with coronary artery disease: children with increased risk. Pediatrics 78:330-337
11. Sniderman AD, Teng B, Genest J, Cianflone K, Wacholder S, Kwiterovich Jr PO 1985 Familial aggregation and early expression of hyperapobetalipoproteinemia. Am J Cardiol 55:291-295
12. Freedman DS, Srinivasan SR, Shear CL, Franklin FA, Webber LS, Berenson GS 1986 The relation of apolipoproteins A-I and B in children to parental myocardial infarction. N Engl J Med 315:721-726
13. Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD 2007 Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics 120:e189-e214
14. National Cholesterol Education Program 1992 Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 89(Suppl):525-584
15. Daniels SR, Greer FR, Committee on Nutrition 2008 Lipid screening and cardiovascular health in childhood. Pediatrics 122:198-208
16. Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinberger J 2006 Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 114:2710-27138
17. Wald DS, Bestwick JP, Wald NJ 2007 Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ 335:599-607
18. Schrott HG, Clarke WR, Wiebe DA, Connor WE, Lauer RM 1979 Increased coronary mortality in relatives of hypercholesterolemic school children: the Muscatine study. Circulation 59:320-326
19. Burns TL, Moll PP, Lauer RM 1992 Increased familial cardiovascular mortality in obese schoolchildren: the Muscatine Ponderosity Family Study. Pediatrics 89:262-268
20. Youssef AA, Srinivasan SR, Elkasabany A, Chen W, Berenson GS 2001 Trends of lipoprotein variables from childhood to adulthood in offspring of parents with coronary heart disease: the Bogalusa Heart Study. Metabolism 50:1441-1446
21. Friedman LA, Morrison JA, Daniels SR, McCarthy WF, Sprecher DL 2006 Sensitivity and specificity of pediatric lipid determinations for adult lipid status: findings from the Princeton Lipid Research Clinics Prevalence Program Follow-up Study. Pediatrics 118:165-172
22. Kwiterovich Jr PO, Barton BA, McMahon RP, Obarzanek E, Hunsberger S, Simons-Morton D, Kimm SY, Friedman LA, Lasser N, Robson A, Lauer R, Stevens V, Van Horn L, Gidding S, Snetselaar L, Hartmuller VW, Greenlick M, Franklin Jr F 1997 Effects of diet and sexual maturation of LDL-cholesterol during puberty: the Dietary Intervention Study in Children (DISC). Circulation 96:2526-2533
23. Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL 1997 Apolipoprotein B and AI distributions in the United States. 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem 43:2364-2378
24. Mudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, Kwiterovich Jr PO 2007 Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol 50:1735-1741
25. Srinivasan SR, Frontini MG, Xu J, Berenson GS 2006 Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: the Bogalusa Heart Study. Pediatrics 118:201-206
26. Srinivasan SR, Myers L, Berenson GS 2002 Distribution and correlates of non-high-density lipoprotein cholesterol in children: the Bogalusa Heart Study. Pediatrics 110:e29
27. Freedman DS, Bowman BA, Otvos JD, Srinivasan SR, Berenson GS 2000 Levels and correlates of LDL and VLDL particle sizes among children: the Bogalusa Heart Study. Atherosclerosis 152:441-449
28. Freedman DS, Bowman BA, Otvos JD, Srinivasan SR, Berenson GS 2002 Differences in the relation of obesity to serum triacylglycerol and VLDL subclass concentrations between black and white children: the Bogalusa Heart Study. Am J Clin Nutr 75:827-833
29. Cali AM, Zern TL, Taksali SE, de Oliveira AM, Dufour S, Otvos JD, Caprio S 2007 Intrahepatic fat accumulation and alterations in lipoprotein composition in obese adolescents: a perfect proatherogenic state. Diabetes Care 30:3093-3098
30. Tzou WS, Douglas PS, Srinivasan SR, Chen W, Berenson G, Stein JH 2005 Advanced lipoprotein testing does not improve identification of subclinical atherosclerosis in young adults: the Bogalusa Heart Study. Ann Intern Med 142:742-750
31. Troiano RP, Flegal KM 1998 Overweight children and adolescents: description, epidemiology, and demographics. Pediatrics 101:497-504
32. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH 2003 Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 157:821-827
33. Vos LE, Oren A, Uiterwaal C, Gorissen WH, Grobbee DE, Bots M 2003 Adolescent blood pressure and blood pressure tracking into young adulthood are related to subclinical atherosclerosis: the Atherosclerosis Risk in Young Adults (ARIC) study. Am J Hypertens 16:549-555
34. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S 2004 Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350:2362-2374
35. Janssen I, Katzmarzyk PT, Srinivasan SR, Chen W, Malina RM, Bouchard C, Berenson GS 2005 Utility of childhood BMI in the prediction of adulthood disease: comparison of national and international references. Obes Res 13:1106-1115
36. Urbina EM, Kieltkya L, Tsai J, Srinivasan SR, Berenson GS 2005 Impact of multiple cardiovascular disease risk factors on brachial artery distensibility in young adults: the Bogolusa Heart Study. Am J Hypertens 18:767-771
37. Chen W, Srinivasan SR, Li S, Xu J, Berenson GS 2005 Metabolic syndrome variables at low levels in childhood are beneficially associated with adulthood cardiovascular risk: the Bogalusa Heart Study. Diabetes Care 28:126-131
38. Chen W, Srinivasan SR, Li S, Xu J, Berenson GS 2007 Clustering of long-term trends in metabolic syndrome variables from childhood to adulthood in Blacks and Whites: the Bogalusa Heart Study. Am J Epidemiol 166:527-533
39. Kwiterovich Jr PO, Levy RI, Fredrickson DS 1973 Neonatal diagnosis of familial type-II hyperlipoproteinaemia. Lancet 1:118-121
40. Kwiterovich Jr PO, Fredrickson DS, Levy RI 1974 Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest 53:1237-1249
41. ter Avest E, Sniderman AD, Bredie SJH, Wiegman A, Stalenhoef AFH, de Graaf J 2007 Effect of aging and obesity on the expression of dyslipidaemia in children from families with familial combined hyperlipidemia. Clin Sci 112:131-139
42. Jolliffe CJ, Janssen I 2006 Distribution of lipoproteins by age and gender in adolescents. Circulation 114:1056-1062
43. Magnussen CG, Raitakari OT, Thomson R, Juonala M, Patel DA, Viikari JS, Marniemi J, Srinivasan SR, Berenson GS, Dwyer T, Venn A 2008 Utility of currently recommended pediatric dyslipidemia classifications in predicting dyslipidemia in adulthood: evidence from the Childhood Determinants of Adult Health (CDAH) study, Cardiovascular Risk in Young Finns Study, and Bogalusa Heart Study. Circulation 117:32-42
44. Goldstein JL, Brown MS 2001 Molecular medicine. The cholesterol quartet. Science 292:1310-1312
45. Rader DJ, Cohen J, Hobbs HH 2003 Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 111:1795-1803
46. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG 1973 Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52:1544-1568
47. Kwiterovich PO 2002 Clinical relevance of the biochemical, metabolic and genetic factors that influence low density lipoprotein heterogeneity. Am J Cardiol 90(Suppl 8A):30i-48i
48. Sniderman AD, Scantlebury T, Cianflone K 2001 Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 135:447-459
49. Maslowska M, Wang HW, Cianflone K 2005 Novel roles for acylation stimulatory protein/C3a desArg: a review of recent in vitro and in vivo evidence. Vitam Horm 70:309-332
50. Cortner JA, Coates PM, Gallagher PR 1990 Prevalence and expression of familial combined hyperlipidemia in childhood. J Pediatr 116:514-524
51. Badzioch MD, Igo Jr RP, Gagnon F, Brunzell JD, Krauss RM, Motulsky AG, Wijsman EM, Jarvik GP 2004 Low-density lipoprotein particle size loci in familial combined hyperlipidemia: evidence for multiple loci from a genome scan. Arterioscler Thromb Vasc Biol 24:1942-1950
52. Gagnon F, Jarvik GP, Badzioch MD, Motulsky AG, Brunzell JD, Wijsman EM 2005 Genome scan for quantitative trait loci influencing HDL levels: evidence for multilocus inheritance in familial combined hyperlipidemia. Hum Genet 117:494-505
53. Aouizerat BE, Allayee H, Bodnar J, Krass KL, Peltonen L, de Bruin TW, Rotter JI, Lusis AJ 1999 Novel genes for familial combined hyperlipidemia. Curr Opin Lipidol 10:113-122
54. Lusis AJ, Fogelman AM, Fonarow GC 2004 Genetic basis of atherosclerosis: Part I. New genes and pathways. Circulation 10:1868-1873
55. Kalant D, MacLaren R, Cui W, Samanta R, Monk PN, Laporte SA, Cianflone K 2005 C5L2 is a functional receptor for acylation stimulatory protein. J Biol Chem 280:23936-23944
56. Pajukanta P, Lilja HE, Sinsheimer JS, Cantor RM, Lusis AJ, Gentile M, Duan XJ, Soro-Paavonen A, Naukkarinen J, Saarela J, Laakso M, Ehnholm C, Taskinen MR, Peltonen L 2004 Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 36:371-376
57. Allayee H, Krass KL, Pajukanta P, Cantor RM, van der Kallen CJ, Mar R, Rotter JI, de Bruin TW, Peltonen L, Lusis AJ 2002 Locus for elevated apolipoprotein B levels on chromosome 1p31 in families with familial combined hyperlipidemia. Circ Res 90:926-931
58. Kwiterovich Jr PO, Clinical and laboratory assessment of cardiovascular risk in children: guidelines for screening, evaluation and treatment. J Clin Lipidol, in press
59. Kwiterovich PO Jr 2008 Primary and secondary disorders of lipid metabolism in pediatrics. Pediatr Endocrinol Rev 5(Suppl 2):727-738
60. Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J, McCarthy BJ 1990 Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 31:1337-1349
61. Arca M, Zuliani G, Wilund K, Campagna F, Fellin R, Bertolini S, Calandra S, Ricci G, Glorioso N, Maioli M, Pintus P, Carru C, Cossu F, Cohen J, Hobbs HH 2002 Autosomal recessive hypercholesterolemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet 359:841-847
62. Lind S, Olsson AG, Eriksson M, Rudling M, Eggertsen G, Angelin B 2004 Autosomal recessive hypercholesterolemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment. J Intern Med 256:406-412
63. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH 2000 Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 290:1771-1775
64. Lu K, Lee MH, Hazard S, Brooks-Wilson A, Hidaka H, Kojima H, Ose L, Stalenhoef AF, Mietinnen T, Bjorkhem I, Bruckert E, Pandya A, Brewer Jr HB, Salen G, Dean M, Srivastava A, Patel SB 2001 Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet 69:278-290
65. Salen G, von Bergmann K, Lütjohann D, Kwiterovich P, Kane J, Patel SB, Musliner T, Stein P, Musser B 2004 Multicenter Sitosterolemia Study Group. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 109:966-971
66. Horton JD, Cohen JC, Hobbs HH 2007 Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 32:71-77
67. Tall AR, Breslow JL, Rubin EM 2001 Genetic disorders affecting high-density lipoproteins. In: Scriver C, Beaudet A, Sly W, Valle D, eds. The metabolic and molecular bases of inherited disease. 7th ed. New York: McGraw-Hill; 2915-2936
68. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH 2004 Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305:869-872
69. Assmann G, von Ekardstein A, Funcke H 1993 High density lipoproteins, reverse 9cholesterol transport of cholesterol, and coronary artery disease: insights from mutations. Circulation 87(Suppl 4):III28-III34
70. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R 2003 Effect of recombinant Apo A-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290:2292-2300
71. Brunham LR, Singaraja RR, Hayden MR 2006 Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. Annu Rev Nutr 26:105-129
72. Calabresi L, Piscotta L, Costantin A, Frigerio I, Eberini I, Alessandrini P, Arca M, Bon GB, Boscutti G, Busnach G, Frascà G, Gesualdo L, Gigante M, Lupattelli G, Montali A, Pizzolitto S, Rabbone I, Rolleri M, Ruotolo G, Sampietro T, Sessa A, Vaudo G, Cantafora A, Veglia F, Calandra S, Bertolini S, Franceschini G 2005 The molecular basis of lecithin: cholesterol acyltransferase deficiency syndromes. A comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol 25:1972-1978
73. Mahley RW, Huang Y, Weisgraber KH 2006 Putting cholesterol in its place: apoE and reverse cholesterol transport. J Clin Invest 116:1226-1229
74. Janssen I, Katzmarzyk PT, Srinivasan SR, Chen W, Malina RM, Bouchard C, Berenson GS 2005 Combined influence of body mass index and waist circumference on coronary artery disease risk factors among children and adolescents. Pediatrics 115:1623-1630
75. Morrison JA, Friedman LA, Wang P, Glueck CJ 2008 Metabolic syndrome in childhood predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years later. J Pediatr 152:201-206
76. Morrison JA, Friedman LA, Gray-McGuire C 2007 Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study. Pediatrics 120:340-345
77. Kaitosaari T, Rönnemaa T, Raitakari O, Talvia S, Kallio K, Volanen I, Leino A, Jokinen E, Välimäki I, Viikari J, Simell O 2003 Effect of 7-year infancy-onset dietary intervention on serum lipoproteins and lipoprotein subclasses in healthy children in the prospective, randomized Special Turku Coronary Risk Factor Intervention Project for Children (STRIP) study. Circulation 108:672-677
78. Rask-Nissilä L, Jokinen E, Terho P, Tammi A, Lapinleimu H, Rönnemaa T, Viikari J, Seppänen R, Korhonen T, Tuominen J, Välimäki I, Simell O 2000 Neurological development of 5-year-old children receiving a low-saturated fat, low-cholesterol diet since infancy: a randomized controlled trial. JAMA 284:993-1000
79. Raitakari OT, Rönnemaa T, Järvisalo MJ, Kaitosaari T, Volanen I, Kallio K, Lagström H, Jokinen E, Niinikoski H, Viikari JS, Simell O 2005 Endothelial function in healthy 11-year-old children after dietary intervention with onset in infancy: the Special Turku Coronary Risk Factor Intervention Project for children (STRIP). Circulation 112:3786-3794
80. The DISC Collaborative Research Group 1995 The efficacy and safety of lowering dietary intake of total fat, saturated fat, and cholesterol in children with elevated LDL-cholesterol: the Dietary Intervention Study in Children (DISC). JAMA 273:429-1435.
81. Obarzanek E, Hunsberger SA, VanHorn L, Hartmuller VV, Barton BA, Stevens VJ, Kwiterovich PO, Franklin FA, Kimm SY, Lasser NL, Simons-Morton DG, Lauer RM 1997 Safety of a fat-reduced diet: the Dietary Intervention Study in Children (DISC). Pediatrics 100:51-59
82. Simons-Morton DG, Hunsberger SA, Van Horn L, Barton BA, Robson AM, McMahon RP, Muhonen LE, Kwiterovich PO, Lasser NL, Kimm SY, Greenlick MR 1997 Nutrient intake and blood pressure in children: Findings from the Dietary Intervention Study in Children (DISC). Hypertension 29:930-936
83. Owen CG, Whincup PH, Odoki K, Gilg JA, Cook DG 2002 Infant feeding and blood cholesterol: a study in adolescents and a systematic review. Pediatrics 110:597-608
84. Gylling H, Siimes MA, Miettinen TA 1995 Sitostanol ester margarine in dietary treatment of children with familial hypercholestereolemia. J Lipid Res 36:1807-1812
85. Tammi A, Rönnemaa T, Miettinen TA, Gylling H, Rask-Nissilä L, Viikari J, Tuominen J, Marniemi J, Simell O 2002 Effects of gender, apolipoprotein E phenotype and cholesterol-lowering by plant stanol esters in children: the STRIP study. Special Turku Coronary Risk Factor Intervention Project. Acta Paediatr 91:1155-1162
86. Amundsen AL Ose L, Nenseter MS, Ntanios FY 2002 Plant sterol esterenriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia. Am J Clin Nutr 76:338-344
87. Kwiterovich PO 1995 The role of fiber in the treatment of hypercholesterolemic children and adolescents. Pediatrics 96:1005-1010
88. Williams CL, Bollella M, Spark A, Puder D 1995 Soluble fiber enhances the hypocholesterolemic effect of the step I diet in childhood. J Am Coll Nutr 14:251-257
89. Davidson MH, Dugan LD, Burns JH, Sugimoto D, Story K, Drennan K 1996 A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: a controlled, double-blind, crossover study. Am J Clin Nutr 63:96-102
90. Laurin D, Jacques H, Moorjani S, Steinke FH, Gagné C, Brun D, Lupien PJ 1991 Effects of a soy-protein beverage on plasma lipoproteins in children with familial hypercholesterolemia. Am J Clin Nutr 54:98-103
91. Jacques H, Laurin D, Moorjani S, Steinke FH, Gagné C, Brun D, Lupien PJ 1992 Influence of diets containing cow's milk or soy protein beverage on plasma lipids in children with familial hypercholesterolemia. J Am Coll Nutr 11:69S-73S
92. Engler MM, Engler MB, Malloy MJ, Paul SM, Kulkarni KR, Mietus-Snyder ML 2005 Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study). Am J Cardiol 95:869-871
93. McCrindle BW, Helden E, Conner WT 1998 Garlic extract therapy in children with hypercholesterolemia. Arch Pediatr Adolesc Med 152:1089-1094
94. Kaitosaari T, Rönnemaa T, Viikari J, Raitakari O, Arffman M, Marniemi J, Kallio K, Pahkala K, Jokinen E, Simell O 2006 Low-saturated fat dietary counseling starting in infancy improves insulin sensitivity in 9-year-old healthy children: the Special Turku Coronary Risk Factor Intervention Project for Children (STRIP) study. Diabetes Care 29:781-785
95. Hakanen M, Lagström H, Kaitosaari T, Niinikoski H, Näntö-Salonen K, Jokinen E, Sillanmäki L, Viikari J, Rönnemaa T, Simell O 2006 Development of overweight in an atherosclerosis prevention trial starting in early childhood. The STRIP study. Int J Obes 30:618-626
96. Gagne C, Gaudet D, Bruckert E 2002 Ezetimibe Study Group. Efficacy and safety of ezetimibe co-administered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105:2469-2475
97. Horton Jay, Goldstein JL, Brown MS 2002 SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125-1131
98. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S 2003 Report of the National Heart, Lung and Blood Institute Workshop on Lipoprotein (a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 49:1785-1786
99. Farah R, Kwiterovich PO, Neill CA 1977 A study of the dose-effect of cholestyramine in children and young adults with familial hypercholesterolemia. Lancet 1:59-63
100. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L 1996 Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 129:42-49
101. Liacouras CA, Coates PM, Gallagher PR, Cortner JA 1993 Use of cholestyramine in the treatment of children with familial combined hyperlipidemia. J Pediatr 122:477-482
102. Knipscheer HC, Boelen CC, Kastelein JJ, van Diermen DE, Groenemeijer BE, van den Ende A, Büller HR, Bakker HD 1996 Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 39:867-871
103. Lambert M, Lupien PJ, Gagné C, Lévy E, Blaichman S, Langlois S, Hayden M, Rose V, Clarke JT, Wolfe BM, Clarson C, Parsons H, Stephure DK, Potvin D, Lambert J 1996 Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics 97:619-628
104. Stein EA, Illingworth DR, Kwiterovich Jr PO, Liacouras CA, Siimes MA, Jacobson MS, Brewster TG, Hopkins P, Davidson M, Graham K, Arensman F, Knopp RH, DuJovne C, Williams CL, Isaacsohn JL, Jacobsen CA, Laskarzewski PM, Ames S, Gormley GJ 1999 Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 281:137-144
105. de Jongh S, Ose L, Szamosi T, Gagné C, Lambert M, Scott R, Perron P, Dobbelaere D, Saborio M, Tuohy MB, Stepanavage M, Sapre A, Gumbiner B, Mercuri M, van Trotsenburg AS, Bakker HD, Kastelein JJ 2002 Simvastatin in Children Study Group. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 106:2231-2237
106. Dirisamer A, Hachemian N, Bucek RA, Wolf F, Reiter M, Widhalm K 2003 The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation. Eur J Pediatr 162:421-425
107. McCrindle BW, Ose L, Marais AD 2003 Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 143:74-80
108. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Büller HR, Sijbrands EJ, Kastelein JJ 2004 Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 292:331-337
109. Clauss SB, Holmes KW, Hopkins P, Stein E, Cho M, Tate A, Johnson-Levonas AO, Kwiterovich PO 2005 Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 116:682-688
110. Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJ, Hutten BA 2007 A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 27:1803-1810
111. Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg AS, van der Graaf A, de Groot E, Wijburg FA, Kastelein JJ, Hutten BA 2007 Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 116:664-668
112. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ 2002 Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 40:2117-2121
113. Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S 2001 Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 50:1457-1461
114. Freemark M, Bursey D 2001 The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 107:1-7
115. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ 1990 Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264:3007-3012
116. Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, Laffel L, Deeb L, Grey M, Anderson B, Holzmeister LA, Clark N; American Diabetes Association 2005 Care of children and adolescents with type I diabetes. A statement of the American Diabetes Association. Diabetes Care 28:186-212
117. Prescott WA, Streetman DD, Streetman DS 2004 The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome. Ann Pharmacother 38:2105-2114
118. Guttmann-Bauman I 2005 Approach to adolescent polycystic ovary syndrome (PCOS) in the pediatric endocrine community in the U.S.A. J Pediatr Endocrinol Metab 18:499-506
119. Vryonidou A, Papatheodorou A, Tavridou A, Terzi T, Loi V, Vatalas IA, Batakis N, Phenekos C, Dionyssiou-Asteriou A 2005 Association of hyperandrogenic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:2740-2746